We report a bone marrow transplant which was HLA matched, with major and minor ABO and minor RhD incompatibility (anti-RhD antibody) between the donor and recipient. When engraftment occurred, the recipient developed an anti-RhD antibody of donor origin detected by direct and indirect antiglobulin tests (DAT, IAT) and showed signs of mild hemolytic anemia. With the disappearance of the recipient RBCs, the DAT became negative and the hemolysis disappeared, while the anti-RhD alloantibody persisted in the patient's serum. This case emphasizes the importance of close immuno-hematological monitoring in patients undergoing allogeneic BMT with ABO-RhD incompatibility between recipient and donor. Keywords: bone marrow transplantation; ABO-RhD incompatibility; alloantibody; hemolytic anemia A 50-year-old male patient, affected by AML (FAB M5), was referred to us for a BMT from his HLA-identical sister, during his first complete remission after chemotherapy. His pre-transplant RBC phenotype was B CcDee (anti-A titer: IgM 256, IgG 128). Antibody screening (indirect antiglobulin test (IAT) ) and direct antiglobulin test (DAT) were negative. The bone marrow donor was a 40-year-old female, whose RBC phenotype was A ccdee (anti-B titer: IgM 512, IgG 64). The IAT showed the presence of an anti-RhD alloantibody, titer 2. This woman had had no pregnancies and had received blood transfusions a few years previously because of a severe anemia due to a uterine hemorrhage.
and the RBC were removed by sedimentation in 12.5% hydroxyethyl starch. A 636 ml suspension of bone marrow cells with a few red cells (equivalent to 15 ml of whole blood with 40% hematocrit) was obtained. The bone marrow was re-infused into the recipient through a central venous catheter, at a rate of 160 ml/h (infusion time: 4 h). During the aplasic period the patient received 9 units of group O Rh-negative RBC, 12 units of single donor platelets (group AB) and 24 units of random pool platelets (group O), that had been re-suspended in 0.9% saline after the plasma had been removed. All blood products were irradiated to 24 Gy and filtered (RXCL 1 PALL filters for RBC and PL 100 PALL filters for platelets). On day 24, the platelets were Ͼ20 × 10 9 /l and the granulocytes Ͼ0.5 × 10 9 /l; a bone marrrow smear confirmed engraftment. The DAT was weakly positive (IgG+, C3dϪ), while the IAT remained negative; an eluate was inconclusive. RBC ABO grouping test showed the presence of RBC from two different blood groups: group O from RBC transfusions and group B from the recipient. Serum ABO grouping was only positive with A 1 RBC. The anti-A 1 (IgG and IgM) titer was 16. The Rh phenotype also showed two RBC populations, D and C positive, and D and C negative, which appeared as a mixed field pattern in liquid and solid phase tests. Weak clinical and laboratory evidence of hemolysis was present from day 18 (subclinical jaundice, a rise in lactate dehydrogenase and bilirubin, mainly non-conjugated, a fall in haptoglobulin and an increased transfusion requirement). On day 35 the IAT became positive: an anti-RhD alloantibody, titer 4, was identified in the patient's serum. The DAT remained positive for IgG but negative for C3d; the eluate confirmed the presence of an anti-RhD alloantibody. The ABO blood group and Rh phenotype were unchanged. The anti-A 1 (IgG and IgM) titer was 4. Hemolysis and transfusion requirements were decreasing. The patient was discharged and follow-up continued in the day hospital. On discharge no clinical evidence of GVHD was present.
On day 57 the following examinations were carried out: bone marrow aspirate, showing good cellularity and normal trilineage hemopoiesis; an RBC ABO grouping test showed the presence of erythrocytes of two different populations: O from the RBC transfusions and A from the donor (weak mixed field pattern); the serum ABO grouping test was positive only for A 1 RBC, titer 2; the Rh phenotype (ccdee). The IAT was unchanged while the DAT had become nega-tive. In order to determine the chimerism between donor and recipient, bone marrow and blood variable number tandem repeat (VNTR) by PCR was performed on the same day. It revealed the presence of 100% donor cells. Laboratory evidence of hemolysis was still weakly present but had completely disappeared by day 66; the patient had required no transfusions after day 72. The transfused RBC group O were no longer detectable after day 180. Tests 15 months post BMT (October 1997) revealed that the anti-A 1 had disappeared and confirmed the presence of a low titer antiRhD antibody in the serum. Table 1 summarizes the posttransplant follow-up.
Discussion
Patients who undergo BMT with major and minor incompatibilies, risk developing severe acute and delayed hemolytic reactions due to donor or recipient isohemoagglutinins. In order to prevent these complications ABO incompatible bone marrow must be manipulated prior to reinfusion.
1,2 In the case of major ABO incompatibility, RBC must be removed from the donor bone marrow by sedimenting substances such as hydroxyethyl startch (HES). Other techniques include recipient plasma exchange, in order to remove isohemoagglutinins. 3 In the case of minor ABO incompatibility, plasma must be removed from the donor bone marrow.
There may also be major (recipient has anti-RhD antibody) or minor (donor has anti-RhD antibody) incompatibility with the RhD system, 4 which is treated like ABO incompatibility, in order to prevent or reduce post transplant hemolysis.
Because of such incompatibilities with our donor/recipient pair, RBC and plasma were removed from Table 1 Condensed laboratory data the donor bone marrow. In the early post-transplant period, no clinical or laboratory evidence of hemolysis was present. From day 24 the DAT became positive and clinical and laboratory tests revealed hemolysis. Since an eluate was inconclusive, the DAT positivity may have been due to the presence of an anti-RhD alloantibody or to an anti-B alloantibody of donor origin. However, it is unlikely that the latter antibodies could have been passively transmitted from the donor to the recipient, since all plasma was removed from the donor bone marrow and hemolysis was delayed. There are a number of reports in the literature of immune hemolytic anemia after ABO incompatible BMT. Anemia due to isohemoagglutinins of donor origin generally occurs 7-10 days after transplant, with a peak incidence after 15-20 days. 5 This suggests that the most likely cause of hemolysis is antibody production from donor 'passenger' lymphocytes, passive antibody transmission being unlikely.
From day 35 an anti-RhD antibody was detected in the serum and on the RBC. This was confirmed by later tests and was still detectable in October 1997. With the gradual disappearance of the recipient RBC RhD positive cells, the DAT became negative and clinical and laboratory evidence of hemolysis also resolved.
The most likely explanation is that this antibody, which appeared early in the post-transplant period, could have been produced by donor memory B cells. The transfer of active immunity in vaccines (from donor to recipient) could occur by a similar mechanism. The IgG antibody was unlikely to have been produced by a primary immune response, since donor B lymphocytes are not able to mount any immune response during the first year post transplant. Moreover, to mount a primary immune response, B lymphocytes need T lymphocytes, which are usually inactive during the first 6 months post transplant. [6] [7] [8] Such cases have rarely been reported in the literature. 4 The clinical impli-cations emphasize the importance of close immuno-hematological monitoring, in patients undergoing allogenic BMT with ABO-RhD incompatibility.
